Medical care costs according to the stage and subtype of breast cancer in a municipal setting: a case study of Hachioji City, Japan

• Published in: Breast cancer (Tokyo, Japan) Vol. 31; no. 1; pp. 105 - 115
• Main Authors: Nishikawa, Yoshitaka, Agatsuma, Nobukazu, Utsumi, Takahiro, Funakoshi, Taro, Mori, Yukiko, Nakamura, Yuki, Hoshino, Nobuaki, Horimatsu, Takahiro, Saito, Takumi, Kashihara, Soichiro, Fukuyoshi, Jun, Goto, Rei, Toi, Masakazu, Takahashi, Yoshimitsu, Nakayama, Takeo
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.01.2024; Springer
• Subjects: Antimitotic agents; Antineoplastic agents; Breast cancer; Breast Neoplasms - diagnosis; Breast Neoplasms - surgery; Cancer; Cancer Research; Care and treatment; Case studies; Diagnosis; Economic aspects; Female; Health Care Costs; Health insurance industry; Humans; Japan; Lymph Node Excision; Medical care, Cost of; Medical research; Medicine; Medicine & Public Health; Medicine, Experimental; National health insurance; Oncology; Original; Original Article; Surgery; Surgical Oncology; Japan; Case study; Healthcare administrative claims; Breast neoplasms; Medical care costs
• ISSN: 1340-6868; 1880-4233; 1880-4233
• DOI: 10.1007/s12282-023-01517-7

Background It is important to assess whether the early detection of breast cancer affects medical care costs. However, research remains scant on the actual medical care costs associated with breast cancer treatment in Japan. This study aimed to determine the medical care costs of breast cancer treatment based on its stage using national health insurance claims data. Methods This was an observational study including patients with breast cancer who had undergone breast cancer treatment, as defined by the disease name and related treatment codes. Between August 2013 and June 2016, patients who underwent surgical treatment without axillary lymph node dissection and other radical treatment were classified as the curable group, while those who underwent palliative treatment were classified as the non-curable group. Patients were further stratified by subtype. The total and treatment-specific medical care costs for the five years were calculated using the national health insurance claims data of Hachioji City between August 2013 and May 2021. Results The mean total medical care costs for the curable and non-curable groups for the 5 years were JPY 3958 thousand (standard deviation 2664) and JPY 8289 thousand (8482), respectively. The mean medical care costs for specific breast cancer treatment for the curable and non-curable groups were JPY 1142 (728) thousand and JPY 3651 thousand (5337), respectively. Further, human epidermal growth factor receptor 2 + , Hormone + patients had the highest mean cost over the 5 years. Conclusions The results suggest that the early detection of breast cancer may reduce medical care costs at the patient level.